Lexapro (escitalopram) withdrawal, more precisely called discontinuation syndrome, produces symptoms including brain zaps, dizziness, nausea, and mood instability that typically peak at days 4 to 7 after stopping and resolve for most people within two to four weeks on standard doses. Because escitalopram has a half-life of 27 to 32 hours, it clears more slowly than shorter-acting SSRIs like paroxetine or venlafaxine, which is why its discontinuation syndrome is generally less severe but more prolonged than those medications.
The distinction between discontinuation syndrome and addiction matters practically. There is no physical dependence, no tolerance requiring escalating doses, and no compulsive drug-seeking behavior. What happens when you stop escitalopram is that your serotonin system, which has been operating in an SSRI-modified state for months or years, goes through a recalibration period as the drug clears. That recalibration is uncomfortable, but it is time-limited and manageable with the right approach.
Here is the week-by-week timeline, the evidence-based tapering protocol, and how to distinguish discontinuation symptoms from relapse.
What Discontinuation Syndrome Is (and Is Not)
Discontinuation syndrome is caused by the abrupt reduction of serotonergic activity when an SSRI is stopped or the dose is significantly reduced. SSRIs work by blocking the serotonin transporter (SERT), which normally reabsorbs serotonin from the synapse after it has been released. By blocking SERT, escitalopram increases the amount of serotonin available in the synaptic cleft.
Over weeks and months of SSRI treatment, the brain adapts to this elevated serotonin environment: postsynaptic serotonin receptors downregulate (reduce their sensitivity), presynaptic autoreceptors adjust their feedback signaling, and several downstream neurochemical systems recalibrate. When escitalopram is abruptly stopped, serotonin activity falls sharply while the brain’s adapted receptor system is still calibrated for a higher-serotonin state. The mismatch produces the symptoms of discontinuation syndrome, and it persists until the brain re-adapts to baseline serotonin levels.
The clinical mnemonic used to remember discontinuation symptoms is FINISH:
- Flu-like symptoms (fatigue, muscle aches, chills, sweating)
- Insomnia (difficulty falling asleep, vivid dreams)
- Nausea
- Imbalance and dizziness (vertigo, gait unsteadiness)
- Sensory disturbances (brain zaps, electric-shock sensations, visual trails)
- Hyperarousal (anxiety, irritability, agitation)
Brain Zaps: What They Are and Why They Happen
Brain zaps are the most distinctive and often the most alarming symptom of SSRI discontinuation. Patients describe them as brief electrical shock sensations in the head, sometimes accompanied by a brief audio hallucination (a buzzing or zapping sound) and occasionally a split-second visual disturbance. They are often triggered by rapid eye movements, which is why many people notice them when they look quickly to the side.
The mechanism is not fully established, but the leading hypothesis involves altered serotonergic modulation of the vestibular system and sensory gating pathways in the brainstem. Serotonin normally modulates how the brain filters and processes sensory signals. When serotonin activity drops sharply during discontinuation, these gating mechanisms become temporarily dysregulated, allowing anomalous sensory signals (the “zap”) to reach conscious awareness. The eye-movement trigger is consistent with vestibulo-serotonergic interaction: eye movements normally produce micro-vestibular signals that are heavily filtered under normal serotonin tone.
Brain zaps are not dangerous. They do not indicate nerve damage, seizure activity, or any structural brain problem. They resolve as serotonin signaling re-establishes normal baseline tone, typically within two to four weeks for most patients on standard doses, though in some cases after long-term high-dose use they can persist for several months. A slow, hyperbolic taper essentially eliminates them as a symptom.
Week-by-Week Timeline After Stopping Lexapro
The timeline below applies to adults stopping a standard dose of 10 to 20mg after at least six months of use, with no taper (cold turkey). Duration and severity scale with dose and length of use.
| Timeframe | What Typically Happens | Severity (Standard Dose) |
|---|---|---|
| Days 1-3 | Drug clears; first symptoms appear: mild dizziness, mild fatigue, some nausea. Brain zaps may begin by day 3. | Mild |
| Days 4-7 | Peak symptom window: brain zaps most frequent, nausea may be significant, mood instability, irritability, insomnia. Most people find this the hardest phase. | Moderate to Severe |
| Week 2 | Physical symptoms (nausea, dizziness) begin to improve. Brain zaps decrease in frequency. Emotional sensitivity and irritability may persist. | Moderate, improving |
| Week 3 | Most physical symptoms resolved. Emotional blunting that was present on Lexapro typically starts to lift. Residual brain zaps in some people. | Mild |
| Week 4+ | Majority of physical discontinuation symptoms resolved. Watch for emerging depressive or anxiety symptoms (may be relapse vs. ongoing discontinuation syndrome). | Minimal to none |
| Long-term users (5+ years, 20mg) | Timeline extends: symptoms may persist 4-8 weeks or longer. Hyperbolic tapering strongly recommended to avoid this scenario. | Potentially severe without taper |
What Makes Discontinuation Syndrome Worse or Better
Duration of use is the single strongest predictor of discontinuation severity. Someone who took 10mg for six months will have a substantially easier experience stopping than someone who took 20mg for five years. The brain’s adaptive changes to chronic SSRI exposure are deeper and more entrenched after longer treatment, requiring more time to reverse.
Dose is the second major factor. Escitalopram occupies approximately 80% of SERT at 10mg and approximately 90% at 20mg. The jump from 80% to 90% occupancy sounds small in absolute terms, but the relationship between dose and SERT occupancy is nonlinear, which has direct implications for tapering strategy (discussed below).
History of anxiety disorders predicts worse discontinuation. People with generalized anxiety disorder or panic disorder may have more severe hyperarousal symptoms during discontinuation, partly because their baseline neurochemistry is already sensitive to serotonin fluctuations.
Speed of the previous taper (or absence of one) is entirely within your control. This is the most modifiable predictor of discontinuation severity. A thoughtful, slow taper is the single most effective intervention available.
Standard vs. Hyperbolic Tapering: The Critical Difference
The conventional tapering approach taught in many clinical settings is linear: reduce from 20mg to 10mg, then from 10mg to 5mg (or 0mg). This approach is pharmacologically naive about how SSRIs actually work at the receptor level.
In 2019, Mark Horowitz and David Taylor published a paper in The Lancet Psychiatry demonstrating that SERT occupancy by escitalopram follows a hyperbolic (not linear) dose-response curve. At 20mg, approximately 90% of SERT is occupied. At 10mg, approximately 80% is occupied. At 5mg, approximately 65% is occupied. At 1mg, approximately 30% is occupied.
The clinical implication is direct: going from 10mg to 0mg (which seems like a small step) actually produces a much larger change in serotonin signaling than going from 20mg to 10mg. The dose reductions that cause the most severe discontinuation symptoms are the ones in the lower dose range, not the higher dose range. A linear taper gets this exactly backwards.
The hyperbolic taper reduces doses by a percentage of the current dose rather than a fixed amount. A conservative hyperbolic schedule for someone at 20mg might look like: 20mg → 15mg → 10mg → 7mg → 5mg → 3mg → 2mg → 1mg → 0.5mg → 0. Each step takes two to four weeks or longer, depending on individual response.
| Feature | Standard Linear Taper | Hyperbolic Taper (Horowitz-Taylor) |
|---|---|---|
| Dose reductions | Fixed mg amounts (e.g., 10mg steps) | Percentage reductions (e.g., 10-25% of current dose) |
| SERT occupancy change at each step | Uneven; largest change at low doses | More even across all steps |
| Discontinuation symptom severity | Often severe at final step (e.g., 5mg to 0) | Substantially reduced or eliminated |
| Duration of full taper | Weeks to a few months | Months to over a year for long-term high-dose users |
| Requires liquid formulation? | No (pills work) | Often yes, for low-dose accuracy |
| Evidence base | Traditional practice; limited RCT data | Pharmacokinetic modeling + growing clinical evidence |
Using Liquid Escitalopram for Micro-Tapering
Escitalopram is available as an oral liquid solution at a concentration of 1mg/mL in most markets. This formulation is essential for accurate micro-tapering at doses below 5mg, where tablet-cutting becomes imprecise and inconsistent.
With the 1mg/mL solution, doses can be measured to 0.1mg accuracy using a standard oral syringe. A patient tapering from 1mg to 0.5mg to 0.25mg to 0mg can do so precisely, with each step producing a controlled, predictable reduction in SERT occupancy. Some patients and prescribers use the “Brass Monkey” protocol of diluting the solution further (e.g., 1mL of 1mg/mL solution in 9mL of water to create a 0.1mg/mL solution) for extremely slow tapers in sensitive individuals.
Prescribers in the UK, Australia, and increasingly in North America are now recognizing the clinical value of prescribing the liquid formulation specifically for tapering purposes. If your prescriber is unfamiliar with this approach, the Horowitz and Taylor 2019 Lancet Psychiatry paper is the appropriate reference to bring to that conversation.
Relapse vs. Discontinuation Syndrome: How to Tell Them Apart
The most common clinical confusion during SSRI discontinuation is distinguishing emerging symptoms of relapse (the original depressive or anxiety disorder returning) from ongoing discontinuation syndrome. The distinction matters because relapse requires treatment, while discontinuation syndrome resolves on its own.
Three features reliably differentiate them:
Timing: Discontinuation symptoms begin within two to five days of stopping or reducing the dose and follow the timeline described above. Relapse after stopping antidepressants typically does not begin until at least two to three months after the drug has fully cleared. If you are feeling significantly worse at day five after stopping, that is almost certainly discontinuation syndrome, not relapse.
Symptom character: Discontinuation syndrome includes symptoms that were not present before treatment or that are neurological in character: brain zaps, dizziness, nausea, paresthesias (tingling), visual disturbances. Relapse looks like the original disorder: the specific depressive or anxiety symptoms you had before treatment, returning gradually.
Response to resuming medication: If symptoms resolve within 24 to 48 hours of taking a dose of escitalopram, they were almost certainly discontinuation symptoms. Relapse does not remit within 48 hours of restarting medication (SSRIs take weeks to produce therapeutic effects).
Understanding the full context of Lexapro within the broader class of antidepressants requires knowing how it compares to alternatives. The detailed comparison of SSRIs versus SNRIs explains why doctors choose one class over the other and how discontinuation profiles differ across medications. For patients who received gabapentin as an adjunct to escitalopram (common in anxiety with neuropathic features), gabapentin has its own discontinuation considerations that need to be addressed separately from the escitalopram taper. Any tapering plan for a prescription medication should be coordinated with a prescriber; the question of who manages that process, generalist or specialist, is covered in the family medicine versus internal medicine guide.
Frequently Asked Questions About Lexapro Withdrawal
How long does Lexapro withdrawal last?
For most people stopping 10 to 20mg after six to twelve months of use, discontinuation symptoms peak at days 4 to 7 and largely resolve by weeks 2 to 4. People who used 20mg for five or more years may have symptoms lasting 4 to 8 weeks or longer. A hyperbolic taper, reducing by a percentage of the current dose rather than a fixed amount, can reduce this timeline significantly by avoiding the abrupt serotonin drop that drives most symptoms.
What do brain zaps feel like and are they dangerous?
Brain zaps feel like brief electrical shock sensations inside the skull, often lasting a fraction of a second, sometimes accompanied by a buzzing or zapping sound and a momentary visual disturbance. They are frequently triggered by rapid eye movements. Despite being alarming, brain zaps are not dangerous. They do not indicate nerve damage, seizure activity, or structural brain injury. They are caused by temporary dysregulation of serotonin-mediated sensory gating and resolve as serotonin signaling recalibrates to baseline.
What does Lexapro withdrawal look like week by week?
Days 1 to 3: mild dizziness, early nausea, fatigue as the drug begins to clear. Days 4 to 7: peak symptoms including brain zaps, significant nausea, mood instability, and insomnia. Week 2: physical symptoms begin improving; brain zaps decrease in frequency. Week 3: most physical symptoms resolved, emotional sensitivity normalizing. Week 4 and beyond: residual symptoms minimal for standard-dose users; watch for relapse vs. discontinuation distinction at the 2-month mark.
Is Lexapro withdrawal dangerous?
Lexapro discontinuation syndrome is not medically dangerous in the sense of being life-threatening. It does not cause seizures (unlike benzodiazepine or alcohol withdrawal, which carry seizure risk). However, the mood instability and emotional dysregulation during peak discontinuation can be significant, particularly for people with a history of suicidality. Any worsening of suicidal thoughts during discontinuation requires immediate clinical contact. For most people, it is uncomfortable and time-limited, not dangerous.
Should I taper Lexapro or stop cold turkey?
For doses above 5mg after more than 8 weeks of use, tapering is strongly recommended. Cold turkey stopping is associated with significantly more severe and prolonged discontinuation symptoms. The evidence-based approach is a hyperbolic taper: reduce by a percentage of your current dose (not a fixed amount) at each step, taking 2 to 4 weeks per step. This requires the oral liquid formulation for accurate dosing at low doses and should be done in coordination with your prescriber.
Taper Slowly, With Support, and With a Clear Plan
The most common mistake people make when stopping Lexapro is going too fast. A discontinuation syndrome that lasts six months is almost always the result of an inadequate taper rather than something inherent to the patient. The brain’s serotonin system adapted to this medication over months or years; giving it the equivalent amount of time to readapt on the way out is not excessive caution, it is pharmacologically appropriate.
Work with your prescriber to access the liquid formulation. Use the hyperbolic approach. Give each dose step at least two to four weeks, and longer if symptoms are significant at any stage. Document your symptoms so you can distinguish ongoing discontinuation from relapse at the two-month mark. And recognize that the goal is not stopping as fast as possible, but stopping in a way that allows you to maintain your quality of life through the process.